Dutasteride Improves Objective and Subjective Disease Measures in Men With Benign Prostatic Hyperplasia and Modest or Severe Prostate Enlargement

Journal of Urology

Volumn 176, Issue 3, 2006, Pages 1045-1050

  Gittelman, Marc ^a   Ramsdell, Joe ^b   Young, Jay ^c   McNicholas, Tom ^d  

^a South Florida Medical Research   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c South Orange County Medical Research Center   (United States)

^d LISTER HOSPITAL   (United Kingdom)

Author keywords

dutasteride; prostate; prostatic hyperplasia; urination disorders

Indexed keywords

DUTASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; ORGAN SIZE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; URINE FLOW RATE; URINE RETENTION;

AGED; AGED, 80 AND OVER; AZASTEROIDS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX;

EID: 33746580539     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.04.032     Document Type: Article

References (25)

1. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474
2. Jacobsen S.J., Girman C.J., and Lieber M. Natural history of benign prostatic hyperplasia. Urology 58 suppl (2001) 5
3. Jacobsen S.J., Girman C.J., Jacobson D.J., and Liebert M.M. Long-term (92-month) natural history of changes in lower urinary tract symptom severity. BJU Int 86 (2000) 248
4. Lee A.J., Russell A.W., Garraway W.M., and Prescott R.J. Three-year follow up of a community based cohort of men with untreated benign prostatic hyperplasia. Eur Urol 30 (1996) 11
5. Meigs J.B., Barry M.J., Giovannucci E., and Kawachi I. Incidence rates and risk factors for acute urinary retention. the health professionals follow up study. J Urol 162 (1999) 376
6. Anderson J.B., Roehrborn C.G., Schalken J.A., and Emberton M. The progression of benign prostatic hyperplasia. examining the evidence and determining the risk. Eur Urol 39 (2001) 390
7. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 suppl (1991) 4
8. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Natural history of prostatism. risk factors for acute urinary retention. J Urol 158 (1997) 481
9. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
10. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
11. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T., Roehrborn C., et al. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488
12. McConnell J.D., Bruskewitz R., Walsh P.C., Andriole G., Lieber M.M., Holtgrewe H.L., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557
13. Boyle P., Gould A.L., and Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride. meta-analysis of randomised clinical trials. Urology 48 (1996) 398
14. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179
15. Roehrborn C.G., Andriole G., Schalken J.A., Wilson T., and Clark R.V. Dutasteride, a novel dual 5alpha-reductase inhibitor, reduces serum DHT to a greater extent than finasteride and achieves finasteride maximal reduction in a larger proportion of patients (2003) Presented at Congress of the European Association of Urology, Madrid, Spain, March
16. Roehrborn C.G., Lukkarinen O., Mark S., Siami P., Ramsdell J., and Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride. results of 4-year studies. BJU Int 96 (2005) 572
17. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al., PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate. results of a four-year, randomized trial comparing finasteride versus placebo. Urology 54 (1999) 662
18. Abrams P., Schafer W., Tammela T.L.J., Barrett D.M., Hedlund H., Rollema H.J., et al. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. J Urol 161 (1999) 1513
19. Marberger M.J., and PROWESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia. a double-blind, placebo-controlled, multicenter study. Urology 51 (1998) 677
20. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533
21. Hudson P.B., Boake R., Trachtenberg J., Romas N.A., Rosenblatt S., Narayan P., et al., The North American Finasteride Study Group. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology 53 (1999) 690
22. Lowe F.C., McConnell J.D., Hudson P.B., Romas N.A., Boake R., Lieber M., et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 61 (2003) 791
23. Vaughan D., Imperato-McGinley J., McConnell J., Matsumoto A.M., Bracken B., Roy J., et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 60 (2002) 1040
24. Marberger M.J., Anderson J.T., Nickel J.C., Malice M.P., Gabriel M., Pappas F., et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Eur Urol 38 (2000) 563
25. Lieber M.M., Jacobsen S.J., Roberts R.O., Rhodes T., and Girman C.J. Prostate volume and prostate-specific antigen in the absence of prostate cancer. a review of the relationship and prediction of long-term outcomes. Prostate 49 (2001) 208